Quick Answer
Adaptimmune Therapeutics PLC reported Total Revenue of $178.03 million for fiscal year 2024.
Adaptimmune Therapeutics PLC — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $178.03M +195.3% |
$60.28M +122.0% |
$27.15M +341.5% |
$6.15M +55.4% |
$3.96M +252.8% |
$1.12M -98.1% |
| Revenue (ASC 606) | $178.03M +195.3% |
$60.28M +122.0% |
$27.15M +341.5% |
$6.15M +55.4% |
$3.96M +252.8% |
$1.12M -98.1% |
| Net Income | -$70.81M +37.8% |
-$113.87M +31.2% |
-$165.46M -4.7% |
-$158.09M -21.5% |
-$130.09M +5.2% |
-$137.16M -43.6% |
| Diluted EPS | -$0.05 +44.4% |
-$0.09 +47.1% |
-$0.17 +0.0% |
-$0.17 -13.3% |
-$0.15 +31.8% |
-$0.22 |
| Total Assets | $245.96M -13.0% |
$282.62M -14.1% |
$328.92M -30.0% |
$469.55M +4.1% |
$451.14M +148.5% |
$181.54M -34.4% |
| Cash and Equivalents | $91.14M -36.7% |
$143.99M +33.3% |
$108.03M -28.0% |
$149.95M +163.6% |
$56.88M +12.8% |
$50.41M -26.3% |
| Long-Term Debt | $50.24M | — | — | — | — | — |
| Stockholders Equity | $11.85M -70.0% |
$39.51M -51.7% |
$81.88M -60.2% |
$205.96M -39.6% |
$341.23M +176.0% |
$123.64M -49.9% |
| R&D Expense | $149.06M +17.8% |
$126.51M -1.0% |
$127.73M +15.0% |
$111.09M +21.3% |
$91.57M -6.1% |
$97.50M -0.8% |
| Operating Income | -$68.76M +50.8% |
-$139.74M +14.8% |
-$163.97M -1.1% |
-$162.25M -21.6% |
-$133.41M +4.6% |
-$139.77M -69.7% |
| Shares Outstanding | 1.54B +12.7% |
1.36B +38.1% |
987.11M +6.3% |
928.55M -0.0% |
928.75M +47.2% |
631.00M +0.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $13.68M | -89.3% | +87.7% |
| Revenue (ASC 606) | June 30, 2025 | $13.68M | -89.3% | +87.7% |
| Net Income | June 30, 2025 | -$30.34M | -143.6% | +36.2% |
| Diluted EPS | June 30, 2025 | -$0.02 | -150.0% | +33.3% |
| Total Assets | June 30, 2025 | $130.63M | -59.4% | -17.4% |
| Cash and Equivalents | June 30, 2025 | $26.06M | -87.7% | -36.5% |
| Long-Term Debt | June 30, 2025 | $25.68M | +2.9% | +1.0% |
| Stockholders Equity | June 30, 2025 | -$70.96M | -173.7% | -89.6% |
| R&D Expense | June 30, 2025 | $22.98M | -43.2% | -20.4% |
| Operating Income | June 30, 2025 | -$30.29M | -144.1% | +33.8% |
| Shares Outstanding | June 30, 2025 | 1.59B | +3.7% | +2.8% |
- Adaptimmune Therapeutics PLC reported Total Revenue of $178.03 million for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed an increase of +195.3% in Total Revenue compared to the prior fiscal year.
- Adaptimmune Therapeutics PLC reported Revenue (ASC 606) of $178.03 million for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed an increase of +195.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Adaptimmune Therapeutics PLC reported Net Income of -$70.81 million for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed an increase of +37.8% in Net Income compared to the prior fiscal year.
- Adaptimmune Therapeutics PLC reported Diluted EPS of $0.05 per share (loss) for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed an increase of +44.4% in Diluted EPS compared to the prior fiscal year.
- Adaptimmune Therapeutics PLC reported Total Assets of $245.96 million for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed a decrease of -13.0% in Total Assets compared to the prior fiscal year.
- Adaptimmune Therapeutics PLC reported Cash and Equivalents of $91.14 million for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed a decrease of -36.7% in Cash and Equivalents compared to the prior fiscal year.
- Adaptimmune Therapeutics PLC reported Long-Term Debt of $50.24 million for fiscal year 2024.
- Adaptimmune Therapeutics PLC reported Stockholders Equity of $11.85 million for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed a decrease of -70.0% in Stockholders Equity compared to the prior fiscal year.
- Adaptimmune Therapeutics PLC reported R&D Expense of $149.06 million for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed an increase of +17.8% in R&D Expense compared to the prior fiscal year.
- Adaptimmune Therapeutics PLC reported Operating Income of -$68.76 million for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed an increase of +50.8% in Operating Income compared to the prior fiscal year.
- Adaptimmune Therapeutics PLC reported Shares Outstanding of 1.54 billion shares for fiscal year 2024.
- Adaptimmune Therapeutics PLC showed an increase of +12.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: